Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label phase 3 LITESPARK-012 study.
Oct 2026· Annals of Oncology· 0 citations· 24 references
Medicine
TL;DR
Neither addition of the HIF-2α inhibitor belzutifan nor the CTLA-4 inhibitor quavonlimab to pembrolizumab plus lenvatinib improved outcomes in participants with previously untreated advanced RCC versus pembrolizumab and lenvatinib alone.
Abstract
Background
Pembrolizumab plus lenvatinib is a first-line standard of care for advanced clear-cell renal-cell carcinoma (ccRCC). The phase 3 LITESPARK-012 study (NCT04736706) evaluated efficacy and safety of adding belzutifan (HIF-2α inhibitor) or quavonlimab (anti-CTLA-4) to this regimen.
Participants
AND
Methods
Adults with previously untreated advanced ccRCC were randomized 1:1:1 to 400 mg pembrolizumab IV Q6W plus 20 mg lenvatinib orally daily and 120 mg belzutifan orally daily (Arm A); coformulated quavonlimab/pembrolizumab 25 mg/400 mg IV Q6W (collectively called MK-1308A) plus lenvatinib (Arm B); or standard-of-care pembrolizumab plus lenvatinib (Control). Treatment continued until progression, unacceptable toxicity, or withdrawal from study; pembrolizumab or quavonlimab/pembrolizumab were administered for a maximum of ∼2 years. Progression-free survival (PFS) by blinded independent central review and overall survival (OS) were dual primary endpoints, tested in all randomized participants for Arm A versus Control, and in participants with IMDC intermediate/poor risk or all participants for Arm B versus Control. Safety was a secondary endpoint.
Results
Overall, 560 participants were randomized to Arm A, 562 to Arm B, and 566 to Control. As of the data cutoff date (February 4, 2026), median follow-up was 43.6 months (range, 31.8-57.4). Among all participants, median PFS was 20.8 months in Arm A (HR vs Control: 1.08, 95%CI 0.93-1.26; P=0.8408), 20.7 months in Arm B (HR vs Control: 1.07, 95%CI 0.92-1.25; nominal P=0.8174), and 23.7 months in the Control arm; median OS was 52.0 months in Arm A (HR vs Control: 1.04, 95%CI 0.87-1.25; P=0.6622), not reached (NR) in Arm B (HR vs Control: 1.12, 95%CI 0.94-1.35; nominal P=0.8955), and NR in the Control arm. Among participants with intermediate/poor risk, median PFS was 20.5 months in Arm B and 23.5 months in the Control arm (HR 1.12, 95%CI 0.94-1.33; P=0.8954); median OS was 39.1 versus 46.2 months (HR 1.17, 95%CI 0.96-1.42; P=0.9419). Any-grade all-cause adverse events led to any-drug discontinuation in 51.6%, 51.4%, and 36.2% of participants in the A, B, and Control arms.
Conclusions
Neither addition of the HIF-2α inhibitor belzutifan nor the CTLA-4 inhibitor quavonlimab to pembrolizumab plus lenvatinib improved outcomes in participants with previously untreated advanced RCC versus pembrolizumab and lenvatinib alone. Higher drug discontinuation rates due to adverse events occurred in the investigational arms. Efficacy and safety of standard-of-care pembrolizumab plus lenvatinib was consistent with prior reports.
BACKGROUND
Pembrolizumab plus chemotherapy with a platinum-based agent and pemetrexed is a widely used standard first-line treatment option for patients with programmed death ligand 1 (PD-L1)-negative advanced nonsquamous non-small-cell lung cancer (NSCLC) without targetable genomic alterations, but outcomes remain sub...
Fei Zhou, Xiang-Jiao Meng, Qing-Qing Ding et al.· New England Journal of Medic...· 0 citations
The phase III KEYFORM-007 study (ClinicalTrials.gov identifier:
NCT05064059
) evaluated the efficacy and safety of coformulated favezelimab/pembrolizumab versus standard-of-care (SOC) in PD-L1–positive microsatellite stable/mismatch repair proficient (MSS/pMMR) metastatic colorectal cancer (mCRC). We present re...
N. Segal, Maria Passhak, F. Kose et al.· JCO Oncology Advances· 0 citations
BACKGROUND
Pembrolizumab, alone or combined with platinum-based chemotherapy, is a standard first-line treatment for patients with metastatic non-small-cell lung cancer (NSCLC) without actionable oncogenic alterations and with high programmed death-ligand 1 (PD-L1) expression. We conducted a head-to-head comparison of...
R. Descourt, A. Mogenet, Maelys Consigny et al.· Annals of Oncology· 0 citations
Background Pembrolizumab–lenvatinib (P/L) is a standard option for patients with advanced or metastatic endometrial cancer (a/m EC) progressing after platinum-based chemotherapy, based on the KEYNOTE-775 trial. However, concerns remain regarding its real-world applicability, particularly in older, frailer patients and...
D. B. Roufai, L. Mansi, M. H. Diallo et al.· ESMO Open· 0 citations
Background There is no standard second-line treatment for patients with platinum refractory advanced B3-Thymoma (T) and thymic carcinoma (TC). In this population, the PECATI trial testing lenvatinib plus pembrolizumab met its primary endpoint, with 5-month progression-free survival (PFS) of 88.0% (90% CI: 73.5–94.8). M...
Jordi Remon, Paolo Bironzo, Nicolas Girard et al.· Mediastinum· 0 citations
BACKGROUND
Prognosis is poor for patients with recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC), warranting novel treatments. Epidermal growth factor receptor (EGFR) and MET are overexpressed in HNSCC and contribute to cancer progression and metastasis. Amivantamab, an EGFR-MET bispecific antibody,...
Hsiang-Fong Kao, K. Harrington, A. Bhatia et al.· Clinical Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.